Amphiregulin (AREG): Complete Research Profile — ADAM10/17 Ectodomain Shedding, ErbB1/ErbB4 Transactivation, Epithelial Barrier Repair Mechanisms, Regulatory T Cell Amplification, Tumor Immune Evasion Biology, and Research Applications (2026)

# Amphiregulin (AREG): Complete Research Profile — ADAM10/17 Ectodomain Shedding, ErbB1/ErbB4 Transactivation, Epithelial Barrier Repair Mechanisms, Regulatory T Cell Amplification, Tumor Immune Evasion Biology, and Research Applications (2026)

Introduction

Amphiregulin (AREG) occupies a paradoxical niche in the EGF superfamily: it is simultaneously an essential tissue repair cytokine and a driver of immune suppression and cancer progression. First isolated from MCF-7 breast cancer cells treated with phorbol ester by Shoyab et al. in 1988, AREG was named for its bifunctional growth-regulatory activity — stimulating normal keratinocyte proliferation while inhibiting cancer cell lines in a context-dependent manner. This early ambiguity foreshadowed the complex biology that makes AREG a compelling subject for research investigators studying epithelial homeostasis, inflammatory resolution, and tumor microenvironment (TME) remodeling.

AREG is encoded by the AREG gene on chromosome 4q13.3 and is synthesized as a 252-amino acid transmembrane precursor (proAREG). Proteolytic ectodomain shedding by ADAM10 and ADAM17 releases the mature, soluble form (~36–50 kDa after glycosylation) into the extracellular space. The soluble ligand binds EGFR (ErbB1/HER1) with moderate affinity (Kd ~3–10 nM), and has been shown to transactivate ErbB4 in specific cell contexts. Unlike EGF or TGF-α, AREG retains a heparin-binding domain that concentrates it on cell surfaces and extracellular matrix proteoglycans, producing an autocrine/juxtacrine signaling geometry distinct from classical endocrine or paracrine EGF family members.

In the immune compartment, AREG emerges as a major effector of regulatory T cells (Tregs) and group 2 innate lymphoid cells (ILC2s) at barrier sites — lung, intestine, and skin — where it coordinates epithelial repair following inflammatory insult. This non-redundant immunomodulatory function has opened new avenues for understanding why tumors exploit Treg-derived AREG to suppress anti-tumor immunity while simultaneously driving cancer cell proliferation.

For research investigators working with epithelial signaling models, barrier inflammation, or immuno-oncology systems, this profile provides the mechanistic depth required to design, interpret, and troubleshoot AREG-centered experiments.

---

Molecular Structure and Biosynthesis

ProAREG Architecture

Human proAREG (UniProt P15514) comprises:

• •Signal peptide (aa 1–19): directs ER insertion
• •N-terminal prodomain (aa 20–101): ~80 aa cytoplasmic/extracellular spacer; regulates processing efficiency
• •EGF-like domain (aa 102–145): contains the six conserved cysteines forming three disulfide bonds (C1-C3, C2-C4, C5-C6) that define the EGF receptor-binding fold
• •Heparin-binding domain (aa 146–184): arginine/lysine-rich stretch mediating HSPG interaction; absent in EGF, TGF-α
• •Transmembrane domain (aa 185–207): single-pass anchor; I-CLiP substrates retain this after shedding
• •Cytoplasmic tail (aa 208–252): contains tyrosine and threonine phosphorylation sites enabling reverse signaling

The EGF-like domain is necessary and sufficient for EGFR binding. The heparin-binding domain extends biologic half-life by anchoring the shed ectodomain to matrix and cell surface HSPGs, creating a local concentration gradient that drives autocrine signaling in tumor cells.

Glycosylation

ProAREG carries N-linked glycosylation at N-168 (Asn in heparin-binding region) and O-linked glycosylation within the prodomain. The mature shed form migrates at 36–50 kDa on SDS-PAGE despite a predicted mass of ~15 kDa for the core EGF domain, with the heterogeneity attributable to glycoform variation. Investigators should note that glycosylation state affects EGFR binding kinetics and that bacterially expressed recombinant AREG lacks these modifications.

---

ADAM10/ADAM17 Ectodomain Shedding

The constitutive and inducible cleavage of proAREG by ADAM (A Disintegrin and Metalloproteinase) sheddases represents the primary regulatory checkpoint controlling AREG bioavailability.

ADAM17 (TACE): The Primary Sheddase

ADAM17 (tumor necrosis factor-alpha converting enzyme, TACE) is the dominant sheddase for AREG under inflammatory and mitogenic stimulation. Cleavage occurs at the Ala²⁰⁴-Val²⁰⁵ juxtamembrane scissile bond, releasing the ectodomain into the extracellular space. Key regulatory inputs to ADAM17-dependent AREG shedding include:

• •PKC activation (phorbol ester, DAG): the canonical stimulus for AREG shedding; PKCδ/ε phosphorylate iRhom2 (RHBDF2), an ADAM17 regulatory partner, triggering its trafficking from ER to Golgi and then to the plasma membrane
• •iRhom1/iRhom2: pseudoproteases of the rhomboid family that act as ADAM17 chaperones and activity regulators; iRhom2 is expressed selectively in immune cells and is required for ADAM17-mediated TNF shedding; iRhom1 predominates in epithelial cells and governs AREG/TGF-α shedding (Adrain et al., 2012, Science)
• •Integrin engagement: α5β1 ligation to fibronectin activates ADAM17-dependent AREG shedding via FAK/Src signaling
• •GPCR transactivation: LPA, thrombin, and ATP receptor activation converge on Src → ADAM17 → AREG → EGFR axis, a common mechanism for G-protein-coupled receptor cross-talk with EGF signaling

ADAM10: Constitutive Shedding and Notch Crosstalk

ADAM10 mediates constitutive, low-level AREG shedding and is activated downstream of calcium ionophore and certain cytokines (IL-4, IL-13 in type 2 immunity contexts). ADAM10 cleaves proAREG at a slightly different juxtamembrane site relative to ADAM17, potentially yielding ectodomain forms with distinct N-termini and HSPG-binding affinities. Given that ADAM10 is also the primary Notch ligand sheddase, there is potential for coupled regulation of AREG/EGF and Notch signaling at barrier surfaces — a mechanistic link relevant to ILC2/epithelial tuft cell circuits.

Sheddase Inhibitors for Research

Using paired GW280264X (dual block) vs. GI254023X (ADAM10-specific) and MM-131 (ADAM17-specific) allows dissection of which sheddase dominates under specific stimulation conditions.

---

ErbB1 (EGFR) Receptor Signaling

Binding Affinity and Receptor Selectivity

AREG binds EGFR (ErbB1) as its primary receptor with Kd ~3–10 nM in solution-phase assays. Unlike the high-affinity ligands EGF (Kd ~0.1–0.3 nM) and TGF-α (Kd ~0.5 nM), AREG's intermediate affinity means it preferentially signals from cell-surface-retained, HSPG-complexed positions rather than occupying the full available receptor pool. Receptor selectivity:

• •ErbB1 (EGFR): primary receptor; binds domain II/IV of the extracellular region
• •ErbB4: demonstrated by Riese et al.; AREG can transactivate ErbB4 in cells co-expressing both receptors, relevant in neurons, cardiac tissue, and some cancer contexts
• •ErbB2/ErbB3: no direct binding; recruited as heterodimerization partners after EGFR activation

Downstream Signaling Cascades

EGFR autophosphorylation at distinct tyrosine residues recruits different adaptor proteins:

AREG-stimulated EGFR shows a signaling bias toward sustained ERK activation compared to EGF, attributed to its slower receptor internalization kinetics (consequence of HSPG co-receptor retention), which prolongs surface receptor dwell time and endosome-to-nucleus ERK signaling duration. This sustained ERK bias correlates with proliferative and migratory responses rather than acute transcriptional programs.

---

ErbB4 Transactivation

ErbB4 (HER4) is a unique ErbB family member that, upon ligand binding and γ-secretase cleavage of its intracellular domain (4ICD), can translocate to the nucleus and function as a transcriptional co-activator with STAT5. AREG-mediated ErbB4 transactivation has been documented in:

• •Mammary gland alveolar development: AREG drives ductal elongation via ErbB1 but alveologenesis involves ErbB4 co-signaling with prolactin/STAT5
• •Neurons: 4ICD nuclear translocation modulates synaptic plasticity genes
• •Treg function: ErbB4 expression in Tregs enables AREG-mediated Treg expansion at barrier sites (Arpaia et al., 2015, Science)

The ErbB4 transactivation mechanism typically involves AREG → ErbB1 → lateral signaling to ErbB1/ErbB4 heterodimers, with the 4ICD fragment providing the transcriptional output. Investigators studying AREG biology in cells expressing ErbB4 should use isoform-selective antibodies (anti-ErbB4 mAb or ErbB4 siRNA knockdown) to decompose ErbB1 vs. ErbB4 contributions.

---

Epithelial Barrier Repair Mechanisms

One of the most physiologically essential functions of AREG is coordinating epithelial repair following damage — a process driven by immune cells, particularly Tregs and ILC2s, that produce AREG at barrier sites.

Lung: Post-Influenza Repair

Arpaia et al. (2015, Science) demonstrated that influenza A infection induces Treg expansion in the lung, and that Treg-derived AREG — but not Treg immunosuppressive function (IL-10/TGF-β) — was required for restoration of lung epithelial integrity. Key mechanistic points:

• •Tregs upregulate AREG expression ~50-fold after lung damage via EGFR signaling on Tregs (autocrine)
• •AREG acts on EGFR-expressing alveolar type II pneumocytes to stimulate proliferation and restoration of surfactant production
• •Treg-specific AREG knockout (Foxp3-Cre × AREG-flox) impaired tissue repair without affecting viral clearance — demonstrating the repair function is mechanistically separable from immunosuppression

Intestine: Helminth-Driven Repair

ILC2s in the intestinal lamina propria upregulate AREG in response to IL-25, IL-33, and TSLP during helminth infection (type 2 immunity). ILC2-derived AREG acts on intestinal epithelial cells to:

• •Promote goblet cell hyperplasia and mucus secretion
• •Stimulate enterocyte tight junction reassembly
• •Drive smooth muscle contractility (via EGFR on myofibroblasts)

Monticelli et al. (2015, Science) showed that ILC2-derived AREG was required for intestinal barrier restoration after helminth clearance, and that adoptive transfer of AREG-sufficient ILC2s into ILC-deficient hosts rescued tissue integrity.

Skin: Wound Healing and Psoriasis

In skin, AREG drives keratinocyte migration and proliferation during wound healing. However, AREG overexpression in chronic inflammation (psoriasis) paradoxically sustains the inflammatory loop:

• •KC-derived AREG → EGFR on fibroblasts → CXCL10, IL-6 production
• •Th2/ILC2-derived AREG → EGFR on keratinocytes → IL-25, TSLP (type 2 amplification loop)

This dual role makes AREG a context-sensitive target: beneficial in acute repair, pathogenic in chronic type 2 skin inflammation.

---

Regulatory T Cell Biology and Immune Suppression

Treg AREG Expression Circuit

Foxp3⁺ Tregs at barrier sites express constitutively high levels of AREG, regulated by:

• •TCR signaling: antigen encounter upregulates AREG transcription via NFAT/AP-1
• •EGFR autocrine loop: AREG → EGFR on Tregs (autocrine) → PI3K-AKT → Foxp3 stabilization
• •IL-2/STAT5: IL-2 receptor signaling upregulates AREG expression in Tregs

The autocrine AREG-EGFR loop in Tregs is noteworthy: AREG promotes Treg survival and Foxp3 expression, creating a self-reinforcing suppressive state. This circuit is amplified in tumor-infiltrating Tregs, where AREG may contribute to their enhanced stability and suppressive potency compared to peripheral Tregs.

Effector T Cell Suppression vs. Repair Function

Critically, Treg-mediated tissue repair via AREG is mechanistically separable from classical immunosuppression (IL-10, TGF-β, CTLA-4 engagement). AREG does not directly suppress effector T cell proliferation or cytokine production at physiological concentrations. Its immune-modulatory role is primarily:

1. Epithelial repair: AREG on epithelial cells → barrier restoration → reduced alarmin (IL-33, TSLP, IL-25) release → dampened innate immune activation

2. Stromal conditioning: AREG on fibroblasts/myofibroblasts → ECM remodeling → reduced inflammatory cell retention

This distinction matters for research design: blocking AREG to enhance anti-tumor immunity risks impairing barrier repair, particularly in lung and gut — a relevant consideration for combination immunotherapy strategies.

---

Tumor Microenvironment and Cancer Biology

AREG as an Oncogene

In cancer, AREG functions as a potent autocrine proliferation factor:

• •Overexpressed in breast, lung, colorectal, head/neck, and pancreatic cancers
• •Correlates with EGFR overexpression and acquired EGFR inhibitor resistance
• •Promotes cancer cell migration, invasion, and anchorage-independent growth

The HSPG-anchoring property of AREG creates high-density autocrine signaling loops on tumor cell surfaces, where AREG shed by one cell is immediately captured by HSPGs and re-presented to EGFR on the same or adjacent cell — a highly efficient autocrine circuit.

KRAS-Driven AREG Upregulation

KRAS mutant cancers (lung adenocarcinoma, colorectal cancer, pancreatic PDAC) constitutively upregulate AREG transcription via:

• •ERK → ELK1/c-Fos transcriptional activation at the AREG promoter
• •mTORC1 → 4EBP1 translational derepression
• •HIF-1α under KRAS-driven Warburg metabolism and tumor hypoxia

KRAS-mutant tumor AREG creates a second-messenger loop that partially bypasses EGFR inhibitor blockade: AREG-driven EGFR signaling can reactivate ERK even under EGFR inhibition at saturating doses, contributing to adaptive resistance observed with erlotinib/gefitinib in KRAS-mutant backgrounds.

Tumor Immune Evasion

Tumor cell-derived AREG and Treg-derived AREG in the TME cooperate to suppress anti-tumor immunity through:

• •Treg autocrine amplification (AREG → EGFR on Tregs → Foxp3 stabilization → sustained immunosuppression)
• •Tumor-Treg crosstalk: Tumor-derived AREG recruits and stabilizes Tregs in the TME independent of classical chemokine gradients
• •NK cell suppression: AREG expression on tumor cells suppresses NKG2D ligand (MICA/MICB) expression via EGFR → AP-1 → transcriptional repression, reducing NK cell recognition
• •Macrophage polarization: AREG drives M2-like macrophage polarization via EGFR on tumor-associated macrophages → STAT3 → IL-10, TGF-β upregulation

This multi-cellular immune evasion network makes AREG a target of interest in combination immunotherapy: anti-AREG strategies may synergize with anti-PD-1/CTLA-4 by simultaneously reducing Treg stability and restoring NK cell and effector T cell function.

---

Transcriptional Regulation of AREG

Promoter Architecture

The AREG promoter (~2 kb upstream of TSS) contains:

• •AP-1 sites (TRE motifs): primary inducible elements; respond to PMA, TNF-α, EGF, KRAS
• •NF-κB binding sites: TNF-α, IL-1β, LPS stimulation drives AREG in epithelial and immune cells
• •Sp1/Sp3 sites: basal constitutive transcription
• •HIF-1α binding (HRE): hypoxia-inducible in tumor contexts
• •STAT6 elements: IL-4/IL-13 signaling in type 2 immune responses (ILC2, Th2, mast cells)

Key Transcriptional Drivers by Cell Type

---

Experimental Protocols and Research Considerations

Recombinant AREG for In Vitro Studies

Commercial recombinant human AREG is available from R&D Systems (Cat# 262-AR), PeproTech (Cat# 100-57), and Sino Biological. Key considerations:

Reconstitution: Lyophilized AREG should be reconstituted in PBS + 0.1% BSA at 100–500 µg/mL stock. Avoid repeat freeze-thaw (aliquot at first thaw). BSA carrier is critical — AREG adsorbs to low-protein-binding tubes but not to BSA-coated surfaces.

Working concentrations:

• •EGFR phosphorylation assays: EC₅₀ ~10–50 ng/mL (keratinocytes); ~1–10 ng/mL (EGFR-overexpressing cancer cell lines)
• •Proliferation assays: 10–100 ng/mL; response plateaus at ~200 ng/mL in most epithelial lines
• •AREG-HSPG interaction studies: use heparinase III pretreatment (2.5 mU/mL, 1h, 37°C) to cleave cell surface HSPGs and shift autocrine to paracrine geometry

Heparin competition: Because AREG binds HSPGs, soluble heparin (10 µg/mL) in the assay medium reduces effective AREG concentration at EGFR. Investigators quantifying AREG potency should specify heparin-free medium unless explicitly studying HSPG effects.

Measuring Endogenous AREG Shedding

ELISA: Quantikine ELISA (R&D Systems DY262) detects soluble AREG in conditioned medium and serum. Sensitivity ~31 pg/mL. Note: the antibody captures the EGF-like domain and detects both full-length shed ectodomain and C-terminal truncation products.

Proximity ligation assay (PLA): For proAREG vs. shed AREG on cell surface, use paired anti-prodomain (clone 155829, R&D) + anti-EGF domain antibodies in PLA format.

Shedding induction protocol:

1. Starve cells 16h in serum-free DMEM + 0.1% BSA

2. Stimulate with PMA (100 nM, 30 min, 37°C) for maximal ADAM17-driven shedding

3. Collect conditioned medium, centrifuge 500×g 5 min to remove cells

4. Measure AREG by ELISA or immunoprecipitation-western

5. Include TAPI-2 (10 µM) control to confirm metalloprotease-dependent shedding

EGFR Phosphorylation Time Course

AREG produces a more sustained EGFR phosphorylation profile than EGF. Recommended time points for pEGFR (Y1068) westerns: 5, 15, 30, 60, 120, 240 min. EGF typically shows peak at 5–15 min then internalization/downregulation; AREG shows sustained pEGFR through 60–120 min in many epithelial lines due to HSPG-mediated surface retention of the ligand-receptor complex.

Treg AREG Expression Protocol

For primary human Treg AREG studies:

1. Isolate CD4⁺CD25⁺CD127ˡᵒ Tregs by FACS or MACS

2. Activate with anti-CD3/CD28 beads (Treg expansion kit, Miltenyi) for 72h

3. Stimulate with rmIL-2 (50 U/mL) + rmEGF (10 ng/mL) for 24h to amplify AREG expression

4. Harvest supernatant for AREG ELISA; cells for AREG mRNA (RT-qPCR, AREG Hs00950669_m1 assay)

5. Control: neutralize with anti-AREG blocking antibody (R&D MAB262, 10 µg/mL) to confirm autocrine contribution

---

PubMed-Cited References

1. Shoyab M, McDonald VL, Bradley JG, Todaro GJ. Amphiregulin: a bifunctional growth-modulating glycoprotein produced by the phorbol 12-myristate 13-acetate-treated human breast adenocarcinoma cell line MCF-7. Proc Natl Acad Sci USA. 1988;85(17):6528-6532.

2. Arpaia N, Green JA, Bhatt B, et al. A Distinct Function of Regulatory T Cells in Tissue Protection. Science. 2015;350(6265):1275-1279. PMID: 26585942

3. Monticelli LA, Osborne LC, Noti M, et al. IL-33 promotes the expansion of ILC2 cells that restore lung anatomy via an amphiregulin-dependent mechanism. Nat Immunol. 2015;16(1):38-45.

4. Adrain C, Zettl M, Bhatt Y, Freeman M, Bhatt B. Tumor necrosis factor signaling requires iRhom2 to promote trafficking and activation of TACE. Science. 2012;335(6065):225-228. PMID: 22246777

5. Busser B, Sancey L, Brambilla E, Coll JL, Hurbin A. The multiple roles of amphiregulin in human cancer. Biochim Biophys Acta. 2011;1816(2):119-131. PMID: 21658434

6. Willmarth NE, Ethier SP. Autocrine and juxtacrine effects of amphiregulin on the proliferative, invasive, and migratory properties of normal and neoplastic human mammary epithelial cells. J Biol Chem. 2006;281(49):37728-37737. PMID: 17050526

---

Summary for Research Investigators

Amphiregulin is a context-dependent EGF family ligand whose biology is defined by three interacting systems: (1) ADAM10/ADAM17 ectodomain shedding as the primary bioavailability checkpoint, (2) HSPG-mediated autocrine/juxtacrine signaling geometry that concentrates activity locally and slows receptor internalization, and (3) a bifunctional role in tissue repair (beneficial, Treg/ILC2-driven, barrier-restorative) versus tumor promotion and immune evasion (pathogenic, KRAS-amplified, TME-suppressive).

Research investigators should control for HSPG interference in concentration-response assays, use isoform-selective ADAM inhibitors (MM-131 vs. GI254023X) to map sheddase contributions, and differentiate ErbB1 vs. ErbB4 contributions in cell contexts where both receptors are expressed. The Treg/ILC2 AREG axis is accessible through primary immune cell co-culture systems or barrier organ-on-chip models that recapitulate damage-repair cycles.

All materials described in this profile are for Research Use Only (RUO). Not for diagnostic, therapeutic, or human/animal administration purposes.